Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription 15.04.2024 5 Am J Hematol 2 Ann Hematol 2 Blood 2 Bone Marrow Transplant 17 Br J Haematol 2 Cancer 1 Cancer Lett 1 Gene 1 Int J Hematol 2 Leuk Res 7 Leukemia 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. SHORT NJ, Jabbour E, Nasr LF, Jain N, et al
   Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
   Am J Hematol. 2024 Apr 12. doi: 10.1002/ajh.27329.
   PubMed        
   
   
2. SHOMALI W, Gotlib J
   World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
   Am J Hematol. 2024;99:946-968.
   PubMed         Abstract available
   
   
3. CIUREA SO, Kongtim P, Srour S, Chen J, et al
   Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML.
   Am J Hematol. 2024;99:890-899.
   PubMed         Abstract available
   
   
4. ORVAIN C, Ali N, Othus M, Rodriguez-Arboli E, et al
   Relative prognostic value of flow cytometric measurable residual disease before allogeneic hematopoietic cell transplantation for adults with MDS/AML or AML.
   Am J Hematol. 2024;99:862-870.
   PubMed         Abstract available
   
   
5. NISHIWAKI S, Sugiura I, Fujisawa S, Hatta Y, et al
   Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission.
   Am J Hematol. 2024;99:806-815.
   PubMed         Abstract available
   
   

   
   Ann Hematol

6. GU Z, Li F, Li M, Wang L, et al
   Upfront allogeneic hematopoietic stem cell transplantation for adult T-cell acute lymphoblastic leukemia/lymphoma in first complete remission: a single-center study.
   Ann Hematol. 2024 Apr 12. doi: 10.1007/s00277-024-05716.
   PubMed         Abstract available
   
   
7. LUO L, Jiao Y, Li Y, Yang P, et al
   Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation treatment for adolescent and adult Tlymphoblastic leukemia /lymphoma: a large cohort multicenter study in China.
   Ann Hematol. 2024 Apr 6. doi: 10.1007/s00277-024-05719.
   PubMed         Abstract available
   
   

   
   Blood

8. BULLINGER L, Kronke J
   Making AML fly too close to the sun.
   Blood. 2024;143:1438-1439.
   PubMed        
   
   
9. BOURGEOIS W, Cutler JA, Aubrey BJ, Wenge DV, et al
   Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.
   Blood. 2024;143:1513-1527.
   PubMed         Abstract available
   
   

   
   Bone Marrow Transplant

10. BARANWAL A, Mangaonkar A, Shah MV, Al-Kali A, et al
    EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant.
    Bone Marrow Transplant. 2024;59:558-560.
    PubMed        
    
    
11. FILIOGLOU D, Truscott L, Reddivalla N, Katsanis E, et al
    Outcomes of haploidentical bone marrow transplantation in infant acute leukemia: a single center experience.
    Bone Marrow Transplant. 2024 Apr 9. doi: 10.1038/s41409-024-02281.
    PubMed        
    
    

    
    Br J Haematol

12. LIGIA S, Passucci M, Assanto GM, D'Elia GM, et al
    Early clearance of hairy cell leukaemia in the bone marrow after first-line treatment with cladribine predicts a favourable outcome.
    Br J Haematol. 2024;204:1288-1292.
    PubMed         Abstract available
    
    
13. MADERO-MARROQUIN R, DuVall AS, Saygin C, Wang P, et al
    Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
    Br J Haematol. 2024;204:1238-1242.
    PubMed         Abstract available
    
    
14. ROY MOULIK N, Keerthivasagam S, Pandey A, Agiwale J, et al
    Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
    Br J Haematol. 2024;204:1249-1261.
    PubMed         Abstract available
    
    
15. LIANG P, Xie Y, Liu Z, Wang D, et al
    Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2024;204:1219-1226.
    PubMed         Abstract available
    
    
16. FIEDLER W
    Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy.
    Br J Haematol. 2024;204:1135-1136.
    PubMed         Abstract available
    
    
17. SUWANNAYING K, Ong AA, Dhaduk R, Pei D, et al
    Quantitative computed tomography analysis of body composition changes in paediatric patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1335-1343.
    PubMed         Abstract available
    
    
18. ZUCENKA A, Griskevicius L
    Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:1227-1231.
    PubMed         Abstract available
    
    
19. NACHMIAS B, Aumann S, Haran A, Schimmer AD, et al
    Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
    Br J Haematol. 2024;204:1146-1158.
    PubMed         Abstract available
    
    
20. JOHNSON IM, Karrar O, Rana M, Iftikhar M, et al
    Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
    Br J Haematol. 2024;204:1232-1237.
    PubMed         Abstract available
    
    
21. ALCAZER V, Morisset S, Rea D, Legros L, et al
    Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
    Br J Haematol. 2024;204:1536-1539.
    PubMed        
    
    
22. ZHANG T, Zhang Y, Zhou M, Zhang Z, et al
    Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:1402-1413.
    PubMed         Abstract available
    
    
23. PATEL SA
    The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
    Br J Haematol. 2024;204:1137-1138.
    PubMed         Abstract available
    
    
24. STENTOFT J
    The Mozart effect in chronic myeloid leukaemia.
    Br J Haematol. 2024;204:1139-1140.
    PubMed         Abstract available
    
    
25. MOSQUERA ORGUEIRA A, Perez Encinas MM, Diaz Varela N, Wang YH, et al
    Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
    Br J Haematol. 2024;204:1529-1535.
    PubMed         Abstract available
    
    
26. CHEN X, Li J, Yu L, Hu W, et al
    High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
    Br J Haematol. 2024;204:1354-1366.
    PubMed         Abstract available
    
    
27. BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
    Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
    Br J Haematol. 2024;204:1367-1374.
    PubMed         Abstract available
    
    
28. LIU HC, Huang YJ, Jaing TH, Wu KH, et al
    Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1(plus) and Day 15 MRD positivity.
    Br J Haematol. 2024;204:1344-1353.
    PubMed         Abstract available
    
    

    
    Cancer

29. JABBOUR E, Haddad FG, Sasaki K, Carter BZ, et al
    Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
    Cancer. 2024 Apr 9. doi: 10.1002/cncr.35317.
    PubMed         Abstract available
    
    
30. LOKE J, Labopin M, Craddock C, Socie G, et al
    Prognostic impact of number of induction courses to attain complete remission in patients with acute myeloid leukemia transplanted with either a matched sibling or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia Working Party
    Cancer. 2024 Apr 6. doi: 10.1002/cncr.35308.
    PubMed         Abstract available
    
    

    
    Cancer Lett

31. ZHAO Y, Chen W, Yu J, Pei S, et al
    TP53 in MDS and AML: Biological and clinical advances.
    Cancer Lett. 2024;588:216767.
    PubMed         Abstract available
    
    

    
    Gene

32. LIU S, Zhan W, He X, Hao M, et al
    ATPR induces acute promyelocytic leukemia cells differentiation and cycle arrest via the lncRNA CONCR/DDX11/PML-RARalpha signaling axis.
    Gene. 2024 Apr 4:148443. doi: 10.1016/j.gene.2024.148443.
    PubMed         Abstract available
    
    

    
    Int J Hematol

33. IRIYAMA N, Iwanaga E, Kimura Y, Watanabe N, et al
    Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
    Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758.
    PubMed         Abstract available
    
    

    
    Leuk Res

34. YIGIT KAYA S, Mutlu YG, Malkan UY, Mehtap O, et al
    Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
    Leuk Res. 2024;140:107495.
    PubMed         Abstract available
    
    
35. MORSY MM, Azzam AY, Elamin O, Elswedy A, et al
    Safety and efficacy of chimeric antigen receptor T-cell therapy for acute myeloid leukemia: A subgroup based meta-analysis.
    Leuk Res. 2024;140:107498.
    PubMed         Abstract available
    
    

    
    Leukemia

36. BELL HL, Blair HJ, Jepson Gosling SJ, Galler M, et al
    Combination p53 activation and BCL-x(L)/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
    Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02241.
    PubMed         Abstract available
    
    
37. FRUCHTMAN H, Avigan ZM, Waksal JA, Brennan N, et al
    Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia.
    Leukemia. 2024 Apr 10. doi: 10.1038/s41375-024-02246.
    PubMed         Abstract available
    
    
38. MCLORNAN DP, Czerw T, Damaj G, Ethell M, et al
    Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee.
    Leukemia. 2024;38:699-711.
    PubMed         Abstract available
    
    
39. LUBKE J, Christen D, Schwaab J, Kaiser A, et al
    Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
    Leukemia. 2024;38:810-821.
    PubMed         Abstract available
    
    
40. SHIMONY S, Bewersdorf JP, Shallis RM, Liu Y, et al
    Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
    Leukemia. 2024;38:762-768.
    PubMed         Abstract available
    
    
41. SEBERT M, Freiman L, Chaffaut C, Guerci A, et al
    Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
    Leukemia. 2024;38:918-922.
    PubMed        
    
    
42. SEVERENS JF, Karakaslar EO, van der Reijden BA, Sanchez-Lopez E, et al
    Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses.
    Leukemia. 2024;38:751-761.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

43. KRISTENSON L, Badami C, Ljungberg A, Islamagic E, et al
    Deletion of the TMEM30A gene enables leukemic cell evasion of NK cell cytotoxicity.
    Proc Natl Acad Sci U S A. 2024;121:e2316447121.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.